Healthcare ❯ Pharmaceuticals ❯ Drug Development ❯ GLP-1 Drugs

Market Competition

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Lilly’s premium price meets a new oral challenger in the GLP‑1 race.

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite